Tumor DNA methylation subtypes and expression levels of CFISH predict response and overall survival to immunochemotherapy.
BACKGROUND Predicting patient response to immunochemotherapy is vital but challenging and poorly studied in the (neo)adjuvant setting. We showed that tumor monocyte content (TMC) predicts overall survival of advanced esophageal cancer (OC) in response to immunochemotherapy. We report clinical outcomes of 35 operable OC...